Skip to content

Cytokinetics CYTK Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements

Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$8.83M+60.6%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$39.87M+66.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.7M-72.5%
Globalstar logo
GlobalstarGSAT
$23.01M+190%
SBA Communications logo
SBA CommunicationsSBAC
$772K-90.8%

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept cytk:NonCashInterestExpensesOnLiabilitiesRelatedToRevenueParticipationRightPurchaseAgreements.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's non cash interest expenses on liabilities related to revenue participation right purchase agreements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's non cash interest expenses on liabilities related to revenue participation right purchase agreements?
Cytokinetics (CYTK) reported non cash interest expenses on liabilities related to revenue participation right purchase agreements of $18.82M in Q1 2026.
How has Cytokinetics's non cash interest expenses on liabilities related to revenue participation right purchase agreements changed year-over-year?
Cytokinetics's non cash interest expenses on liabilities related to revenue participation right purchase agreements increased by 33.7% year-over-year, from $14.08M to $18.82M.
What is the long-term trend for Cytokinetics's non cash interest expenses on liabilities related to revenue participation right purchase agreements?
Over 4 years (2021 to 2025), Cytokinetics's non cash interest expenses on liabilities related to revenue participation right purchase agreements has grown at a 45.8% compound annual growth rate (CAGR), from $12.89M to $58.29M.
What does non cash interest expenses on liabilities related to revenue participation right purchase agreements mean?
Non-cash interest costs related to specific financing agreements like royalty-based debt.
How do you interpret non cash interest expenses on liabilities related to revenue participation right purchase agreements?
An increase reflects the accrual of obligations under complex financing structures, which may impact future cash flows when settled.
How does non cash interest expenses on liabilities related to revenue participation right purchase agreements compare across companies?
Specific to companies using alternative financing structures; less common in traditional debt-heavy industries.